| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/13543784.2015.999154 |
| P698 | PubMed publication ID | 25640877 |
| P50 | author | Umberto Leone Roberti Maggiore | Q61108169 |
| Giorgia Mangili | Q72602431 | ||
| Alice Bergamini | Q87828976 | ||
| Massimo Candiani | Q93004208 | ||
| Simone Ferrero | Q47282621 | ||
| P2093 | author name string | Emanuela Rabaiotti | |
| Patrizia De Marzi | |||
| Riccardo Viganò | |||
| Stefano Salvatore | |||
| Micaela Petrone | |||
| P2860 | cites work | The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies | Q21129302 |
| A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer | Q22001066 | ||
| The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial | Q24629295 | ||
| Targeted anti-vascular therapies for ovarian cancer: current evidence | Q26830287 | ||
| Antibody-based immunotherapy for ovarian cancer: where are we at? | Q27000514 | ||
| BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy | Q27650860 | ||
| Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study | Q27853070 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 | ||
| Structural, functional and therapeutic biology of survivin | Q28235149 | ||
| AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer | Q28251373 | ||
| The phosphatidylinositol 3-Kinase AKT pathway in human cancer | Q29547860 | ||
| Tumor angiogenesis | Q29614938 | ||
| EGFR antagonists in cancer treatment | Q29616740 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial | Q29619615 | ||
| Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial | Q30429122 | ||
| Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. | Q33393879 | ||
| Incorporation of pazopanib in maintenance therapy of ovarian cancer | Q33417673 | ||
| A phase 3 trial of bevacizumab in ovarian cancer | Q34030022 | ||
| The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer | Q34134697 | ||
| Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. | Q34147360 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| WEE1 tyrosine kinase, a novel epigenetic modifier | Q34335765 | ||
| Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay | Q34399808 | ||
| Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. | Q34422265 | ||
| Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials | Q34625332 | ||
| Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis | Q35098091 | ||
| Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. | Q35758403 | ||
| PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations | Q35808438 | ||
| A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas | Q35836463 | ||
| Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. | Q36688029 | ||
| Aberrant lipid metabolism: an emerging diagnostic and therapeutic target in ovarian cancer. | Q36820509 | ||
| OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer | Q36822179 | ||
| Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation | Q37313698 | ||
| A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer | Q37423291 | ||
| The contribution of BRCA1 and BRCA2 to ovarian cancer | Q37453854 | ||
| Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer | Q37474070 | ||
| Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. | Q54566293 | ||
| Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer | Q56807699 | ||
| Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer | Q57416431 | ||
| TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development | Q37803061 | ||
| STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis | Q37825268 | ||
| Monoclonal antibodies therapies for ovarian cancer | Q38078400 | ||
| Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment | Q38115596 | ||
| Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer | Q38122265 | ||
| Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma | Q38128384 | ||
| Novel tyrosine kinase inhibitors for renal cell carcinoma. | Q38168944 | ||
| New perspectives in ovarian cancer treatment. | Q38174975 | ||
| Ganetespib and HSP90: translating preclinical hypotheses into clinical promise | Q38189961 | ||
| PARP inhibitors in ovarian cancer: current status and future promise | Q38194324 | ||
| Novel therapies, including enzastaurin, in the treatment of ovarian cancer | Q38198095 | ||
| MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo | Q38431323 | ||
| Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. | Q39333446 | ||
| Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells | Q39730373 | ||
| Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin | Q40721415 | ||
| AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth | Q42463490 | ||
| A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer | Q43003099 | ||
| Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study | Q43231629 | ||
| Pralatrexate pharmacology and clinical development | Q43619079 | ||
| Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions | Q44286102 | ||
| Incorporation of bevacizumab in the primary treatment of ovarian cancer | Q44579933 | ||
| Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors | Q44649604 | ||
| Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study | Q44846367 | ||
| Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. | Q44959677 | ||
| The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis | Q46535751 | ||
| Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study | Q46630310 | ||
| The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts | Q46652649 | ||
| A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors | Q46879006 | ||
| Expression of heat-shock proteins hsp27, hsp70 and hsp90 in malignant epithelial tumour of the ovaries | Q47869343 | ||
| A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†. | Q52839148 | ||
| Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide). | Q53073221 | ||
| The association of serous tubal intraepithelial carcinoma with gynecologic pathologies and its role in pelvic serous cancer. | Q53234024 | ||
| Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. | Q53337533 | ||
| Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? | Q53438901 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase II clinical trial | Q42824440 |
| P304 | page(s) | 345-362 | |
| P577 | publication date | 2015-02-01 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas | |
| P478 | volume | 24 |
| Q38995020 | Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer. | cites work | P2860 |
Search more.